Elicit Plant Appoints Pam Marrone and Johan de Saegher on Its Board of Directors
Elicit Plant, an agricultural biotechnology company specialized in crops’ resistance to water stress based on a phytosterol-based technology platform, announced today it has appointed Dr. Pam Marrone as Chairwoman of the Board of Directors and Dr. Johan de Saegher as Independent Board Member.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230301005582/en/
Pam Marrone and Johan de Saegher join Elicit Plant's Board of Directors (Photo: Elicit Plant)
Pam is a serial entrepreneur bringing over 30 years of leadership experience in the agricultural biologicals industry. Pam currently serves as Executive Chair of Invasive Species Control Corporation which she cofounded in 2022. Recently, she was Chief Executive Officer of Marrone Bio Innovations (MBI), an agricultural biological company she founded in 2006. In 2013, MBI listed its stock on NASDAQ. Under her leadership, the company commercialized 10 products from six EPA-registered active ingredients, and in 2019 acquired ProFarm Technologies selling bionutrient seed treatments from wood waste. Prior to establishing MBI, Marrone founded AgraQuest in 1995, where she served as CEO, Chairwoman or President until 2006. Pam is a well-recognized leader as evidenced by numerous awards, including the American Chemical Society’s “Kathryn C. Hach Award for Entrepreneurial Success,” “Most Admired CEO, Distinguished Career Award” by the Sacramento Business Journal, the “Sustie” award by the Ecological Farming Association, and the Natural Resources Defense Council (NRDC) Growing Green Award in the “Business Leader” category. Pam is the founder of the Biological Products Industry Alliance, now a trade group of more than 100 companies. Aside from her role as Chairwoman of Elicit Plant, Pam serves on several for-profit and non-profit Boards, including 180 Life Sciences (NASDAQ: ATNF), StemExpress, Pheronym and the Foundation for Food and Agriculture Research.
Johan de Saegher is an accomplished business executive with 30 years of business experience of which 17 years in the crop protection industry. He currently serves as CEO of Bi-PA, a company specialized in developing innovative solutions for pest management. From 2018 to 2022 he held the position of CEO and COO of Belchim Crop Protection NV, a leading European distributor in the crop protection market, based in Belgium, with also activities in North America and Asia. Previously, and until the company was acquired by Eastman Chemical in 2014, Johan worked at Taminco (NYSE) where he held positions as Chief Operating Officer, Vice-President Agrosciences and President Asia/Latin America. He is currently also Chairman of Aphea.bio and holds a board position within Mitsui Agrisciences International.
“I am impressed by the excellent achievements Elicit Plant has accomplished in such a short time. The company’s unique technology platform positively impacts the planet and provides farmers with a natural and efficient solution to address the challenges of climate change. I am looking forward to work alongside the team as it accelerates its growth,” said Pam Marrone.
Johan de Saegher added, “It is an honor to join Elicit Plant’s Board of Directors and contribute to building the company into a large scale and profitable enterprise as it is entering its next phase of development. Through its high value solutions, Elicit Plant offers for row crops a new dimension in abiotic stress management such as drought, safeguarding the yield of the farmer by optimizing the natural response of the plants to the changing environment.”
Jean-François Dechant, Chief Executive Officer and Cofounder of Elicit Plant, said: “Pam and Johan are a wonderful addition as Elicit Plant is entering new markets, expanding its laboratories and diversifying its portfolio of products. At such a strategic time for Elicit Plant, we are grateful for their confidence, and we are all eager to benefit from their knowledge and impressive track records.”
About Elicit Plant
Elicit Plant is an agbiotech company created in 2017 with the ambition to become a sustainability transition champion in agriculture and respond to the global challenges of water stress in crops. Based in Charente (France), the firm has 60 employees across its R&D Center established within a 1,000 ha farm, its offices in Lyon, and its subsidiary in Brazil. Elicit Plant’s proprietary technology is delivered through foliar application of phytosterols, molecules found in plants that reduce crops’ water consumption. Open-field trials have shown an average yield increase of +10 bushels per acre on average. In 2022, Elicit Plant began marketing its BEST-a product line for corn crops in France, and obtained market approvals for Ukraine and Brazil.
For more information: www.elicit-plant.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230301005582/en/
Contact information
Media contact for Elicit Plant
Anne Rein
Strategies & Image (S&I)
+33 6 03 35 92 05
anne.rein@strategiesimage.com
About Business Wire
Business Wire(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer26.4.2024 14:30:00 CEST | Press release
Takeda (TSE:4502/NYSE:TAK) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of fruquintinib, a selective inhibitor of vascular endothelial growth factor receptors (VEGFR) -1, -2 and -3 for the treatment of adult patients with previously treated metastatic colorectal cancer (mCRC). The European Commission (EC) will consider the CHMP positive opinion when determining the potential marketing authorization for fruquintinib for mCRC throughout the European Union (EU), Norway, Liechtenstein and Iceland. If approved, fruquintinib will be the first and only selective inhibitor of all three VEGF receptors approved in the EU for previously treated mCRC.1,2 “People living with metastatic colorectal cancer in the European Union currently have limited treatment options, which can lead to poor outcomes. With this positive opinion for fruquintinib, we are one step closer to potentially offering patients a new
MEDIA ALERT: Wolters Kluwer expert comments on European Parliament vote to pass amendment implementing Basel III reforms26.4.2024 14:00:00 CEST | Press release
The European financial landscape saw a milestone event this week, as the EU Parliament passed the Amendment to Regulation (EU) No 575/2013, implementing the Basel III finalization within Europe. This monumental step forward comes with the adoption of the Capital Requirements Regulation (CRR3) amendments, which are part of a broader legislative package, including amendments to Directive 2013/36/EU, known as the Capital Requirements Directive or CRD. Jeroen Van Doorsselaere, Vice President of Global Product & Platform Management, Wolters Kluwer FRR, said: “The adoption of the Capital Requirements Regulation (CRR3) amendments represents a landmark change for the banking industry, designed to strengthen the framework for risk-based capital requirements and address ESG risks. “This is a major overhaul of the capital requirements framework, impacting various aspects, including credit risk, operational risk, market risk, and the capital floor. Whereas other significant jurisdictions, includin
IonQ Unanimously Appoints Peter Chapman as Next Chairman of the Board of Directors26.4.2024 13:30:00 CEST | Press release
IonQ (NYSE: IONQ), a leader in the quantum computing industry, announced today the appointment of Peter Chapman as its next Chairman of the Board and Harry You as the Lead Independent Director of the Board, effective at the close of IonQ’s upcoming Annual General Meeting on June 5, 2024. Both appointments were disclosed in a proxy statement issued on April 25, 2024. Peter Chapman has also been nominated for re-election as a Class III director at the meeting, and his chairmanship will take effect assuming he is re-elected. “Last quarter we were delighted to have appointed Robert Cardillo and Bill Scannell to our Board of Directors. In addition, the Board unanimously appointed Peter Chapman to serve as its next Chairman following the annual meeting given his half-decade worth of contributions to IonQ and his strong progress transitioning IonQ from an academic to a commercial company,” said Niccolo de Masi, Chairman of the Nominating & Corporate Governance Committee of IonQ’s Board. “Unde
Sealing System launches: XIO – Intelligent Farming26.4.2024 12:17:00 CEST | Press release
XIO – Intelligent Farming, specializes in logistics systems for insect protein production. XIO is a new business unit within Sealing System A/S, one of the leading providers of automated end-of-line packaging lines in Scandinavia. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240426832303/en/ Robotic solution handling Black Soldier Fly Larvae (Photo: Business Wire) “At Sealing System A/S, we believe that practical innovation is the engine of real-world change. With the establishment of, XIO - Intelligent Farming, we are setting new industry standards, emphasizing the importance of intralogistics in the field of insect protein production, and proudly leading the way.” Ole Jensen CEO, Sealing System A/S XIO – Intelligent Farming provides solutions serving various aspects of the insect production, including fully automatic logistics systems, comprehensive data tracking, transfer trolleys and shuttles, as well as robot systems
Tecnotree Achieves Strong Q1 2024 Results with Sustained Revenue Growth and Enhanced Profitability26.4.2024 10:46:00 CEST | Press release
Tecnotree, a global digital platform and services leader for AI, 5G, and cloud-native technologies, today announced its financial results for the first quarter of 2024, demonstrating solid growth with a 4.7% increase in revenue. The company maintained its momentum in driving global sales of its digital platform, in the first quarter of 2024, completing many AIML and digital transformations to key customers, resulting in a significant increase in revenue. The growth was primarily driven by new wins in the LATAM region, while EMEA and APAC regions remain growing markets for the digital platform. Key Q1 Highlights of the financial results: Net sales increased 4.7% to EUR 16.3 (15.5) million. Operating results increased by 22.3% to EUR 4.4 (3.6) million. Earnings per share EUR 0.01 (0.01). Order book at the end of the period increased by 10.3% to EUR 74.8 (67.8) million. Tecnotree achieved several notable milestones in the first quarter. The company solidified its position as a trusted par